A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

NCT05806567 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune System Disorder
Healthy Volunteers

Interventions

DRUG: Belumosudil
DRUG: UGT1A1 victim drug
DRUG: P-gp victim drug
DRUG: OATP1B1/BCRP victim drug

Sponsor

Kadmon, a Sanofi Company